Wealth Enhancement Advisory Services, LLC Allogene Therapeutics, Inc. Transaction History
Wealth Enhancement Advisory Services, LLC
- $55.6 Billion
- Q2 2025
A detailed history of Wealth Enhancement Advisory Services, LLC transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Wealth Enhancement Advisory Services, LLC holds 18,736 shares of ALLO stock, worth $24,731. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,736
Previous 19,260
2.72%
Holding current value
$24,731
Previous $28,000
25.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ALLO
# of Institutions
177Shares Held
165MCall Options Held
202KPut Options Held
76.6K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$24.7 Million0.84% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$21.7 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA12.3MShares$16.2 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$14.6 Million5.97% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.4MShares$13.8 Million1.06% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $190M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...